AtriCure, Inc. – NASDAQ:ATRC
AtriCure stock price today
$35.5
+4.85
+15.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
AtriCure stock price monthly change
+32.17%
month
AtriCure stock price quarterly change
+32.17%
quarter
AtriCure stock price yearly change
-17.39%
year
AtriCure key metrics
Market Cap | 1.49B |
Enterprise value | 1.92B |
P/E | -41.34 |
EV/Sales | 5.83 |
EV/EBITDA | -65.34 |
Price/Sales | 5.80 |
Price/Book | 4.19 |
PEG ratio | 0.21 |
EPS | -0.79 |
Revenue | 414.60M |
EBITDA | -23.18M |
Income | -37.23M |
Revenue Q/Q | 16.42% |
Revenue Y/Y | 18.69% |
Profit margin | -14.06% |
Oper. margin | -12.92% |
Gross margin | 74.44% |
EBIT margin | -12.92% |
EBITDA margin | -5.59% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAtriCure stock price history
AtriCure stock forecast
AtriCure financial statements
| Jun 2023 | 100.91M | -5.11M | -5.07% |
|---|---|---|---|
| Sep 2023 | 98.29M | -9.05M | -9.21% |
| Dec 2023 | 106.54M | -9.78M | -9.19% |
| Mar 2024 | 108.85M | -13.26M | -12.19% |
| Sep 2025 | 130.20M | -6.89M | -5.3% |
|---|---|---|---|
| Oct 2025 | 129.55M | -6.89M | -5.32% |
| Dec 2025 | 140.19M | -4.88M | -3.48% |
| Mar 2026 | 136.03M | -9.06M | -6.66% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 594171000 | 131.74M | 22.17% |
|---|---|---|---|
| Sep 2023 | 600271000 | 137.43M | 22.9% |
| Dec 2023 | 613932000 | 147.76M | 24.07% |
| Mar 2024 | 591628000 | 135.31M | 22.87% |
| Jun 2023 | 3.01M | -16.08M | 2.99M |
|---|---|---|---|
| Sep 2023 | 1.52M | 11.87M | 132K |
| Dec 2023 | 4.03M | -2.78M | 2.35M |
| Mar 2024 | -21.87M | 9.64M | -7.00M |
AtriCure alternative data
| Aug 2023 | 1,050 |
|---|---|
| Sep 2023 | 1,050 |
| Oct 2023 | 1,050 |
| Nov 2023 | 1,050 |
| Dec 2023 | 1,050 |
| Jan 2024 | 1,050 |
| Feb 2024 | 1,050 |
| Mar 2024 | 1,200 |
| Apr 2024 | 1,200 |
| May 2024 | 1,200 |
| Jun 2024 | 1,200 |
| Jul 2024 | 1,200 |
AtriCure other data
78.51%
-18.49%
of ATRC is owned by hedge funds
187
-15
35.87M
-8.29M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 1248 |
| Mar 2024 | 0 | 11616 |
| Apr 2024 | 0 | 1500 |
| May 2024 | 5000 | 1500 |
| Aug 2024 | 0 | 3500 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | YUEN MAGGIE director | Common Stock | 3,500 | $24.07 | $84,245 | ||
Purchase | PRIVITERA SALVATORE officer: Chief Te.. | Common Stock | 5,000 | $22.25 | $111,250 | ||
Sale | NOZNESKY JUSTIN J officer: Chief Mk.. | Common Stock | 1,500 | $24.09 | $36,135 | ||
Sale | NOZNESKY JUSTIN J officer: Chief Mk.. | Common Stock | 1,500 | $30.39 | $45,585 | ||
Sale | DAHLQUIST KARL S. officer: Chief Legal Officer | Common Stock | 1,885 | $32.16 | $60,622 | ||
Sale | NOZNESKY JUSTIN J officer: Chief Mk.. | Common Stock | 1,500 | $36.72 | $55,080 | ||
Sale | DAHLQUIST KARL S. officer: Chief Legal Officer | Common Stock | 8,231 | $37.36 | $307,510 | ||
Option | WIRICK ANGELA L officer: Chief Financial Officer | Common Stock | 5,000 | $16.95 | $84,750 | ||
Option | WIRICK ANGELA L officer: Chief Financial Officer | Non-qualified Stock Option (right to buy) | 5,000 | $16.95 | $84,750 | ||
Option | WHITE ROBERT S. director | Common Stock | 10,000 | $15.96 | $159,600 |
| Patent |
|---|
Grant Filling date: 25 Sep 2019 Issue date: 13 Sep 2022 |
Grant Utility: Clip applier Filling date: 14 Nov 2018 Issue date: 13 Sep 2022 |
Grant Utility: Surgical device Filling date: 16 Nov 2020 Issue date: 9 Aug 2022 |
Grant Filling date: 4 Apr 2019 Issue date: 19 Jul 2022 |
Grant Utility: Occlusion clip Filling date: 11 Jan 2018 Issue date: 19 Jul 2022 |
Application Filling date: 10 Dec 2021 Issue date: 30 Jun 2022 |
Application Filling date: 17 Sep 2021 Issue date: 23 Jun 2022 |
Grant Utility: Vacuum coagulation probes Filling date: 8 Jul 2019 Issue date: 21 Jun 2022 |
Application Filling date: 17 Feb 2022 Issue date: 2 Jun 2022 |
Application Filling date: 8 Dec 2021 Issue date: 19 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 25 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Michael H. Carrel (1971) Chief Executive Officer, Pres & Director | $1,100,000 |
| Mr. Douglas J. Seith (1966) Chief Operating Officer | $693,240 |
| Mr. Salvatore Privitera J.D. (1967) Chief Technical Officer | $471,150 |
| Mr. Justin J. Noznesky (1978) Chief Marketing & Strategy Officer | $470,380 |
Ms. Angela L. Wirick CPA (1978) Chief Financial Officer | $402,240 |
-
What's the price of AtriCure stock today?
One share of AtriCure stock can currently be purchased for approximately $35.5.
-
When is AtriCure's next earnings date?
Unfortunately, AtriCure's (ATRC) next earnings date is currently unknown.
-
Does AtriCure pay dividends?
No, AtriCure does not pay dividends.
-
How much money does AtriCure make?
AtriCure has a market capitalization of 1.49B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.84% to 399.25M US dollars.
-
What is AtriCure's stock symbol?
AtriCure, Inc. is traded on the NASDAQ under the ticker symbol "ATRC".
-
What is AtriCure's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of AtriCure?
Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AtriCure's key executives?
AtriCure's management team includes the following people:
- Mr. Michael H. Carrel Chief Executive Officer, Pres & Director(age: 54, pay: $1,100,000)
- Mr. Douglas J. Seith Chief Operating Officer(age: 59, pay: $693,240)
- Mr. Salvatore Privitera J.D. Chief Technical Officer(age: 58, pay: $471,150)
- Mr. Justin J. Noznesky Chief Marketing & Strategy Officer(age: 47, pay: $470,380)
- Ms. Angela L. Wirick CPA Chief Financial Officer(age: 47, pay: $402,240)
-
How many employees does AtriCure have?
As Jul 2024, AtriCure employs 1,200 workers.
-
When AtriCure went public?
AtriCure, Inc. is publicly traded company for more then 20 years since IPO on 5 Aug 2005.
-
What is AtriCure's official website?
The official website for AtriCure is atricure.com.
-
Where are AtriCure's headquarters?
AtriCure is headquartered at 7555 Innovation Way, Mason, OH.
-
How can i contact AtriCure?
AtriCure's mailing address is 7555 Innovation Way, Mason, OH and company can be reached via phone at +51 37554100.
AtriCure company profile:
AtriCure, Inc.
atricure.comExchange:
NASDAQ
Full time employees:
1,200
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
7555 Innovation Way
Mason, OH 45040
Mason, OH 45040
CIK: 0001323885
ISIN: US04963C2098
CUSIP: 04963C209
